Cancer Advisor

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: June 21, 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Frame...

OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...